Meeting ReportAutosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
KEYWORDS
Cited by (0)
ABC declared having served on the Otsuka Steering Committee and received grant support from CRISP, MODIFIER, and SPRINT. OD declared having served on Steering Committee for the TEMPO studies. RTG declared having received consultancy fees from Abbott/Abbvie, Bayer, Ipsen and Otsuka (all paid to employer UMCG); research support from the Dutch Kidney Foundation and Ipsen. TH declared having received honoraria from Otsuka Europe and Otsuka Japan. SH declared having received consultancy fees and speaker honorarium from Otsuka. BLK declared having received consultancy fees from Rockwell and speaker honoraria from Rockpoint and Sanofi; NIH grant for a study on Living Kidney Donors. Y Pei declared having received consultancy fees from Otsuka. RDP declared having received consultancy fees from Otsuka (all paid to employer Tufts Medical Center), Sanofi-Genzyme, and Vertex; research support from Otsuka. Y Pirson declared having received speaker honorarium from Otsuka. RWS declared having received consultancy fees from Otsuka and research support from NIH on slowing progression of ADPKD. VET declared having received grant support from NIH, NIDDK, and Otsuka. TW declared having received consultancy fees from PKD Foundation; research support from Otsuka; royalties from a joint licensing agreement with Athena Laboratories and Johns Hopkins on sales of PKD gene testing. DCW declared having received consultancy fees from Otsuka. KUE, DO, and RT reported no relevant disclosures.
- 17
Roster is listed in Appendix